ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-OR105

Xenotransplantation and Physiologic Homeostasis: Case Report of a First Living Human Recipient

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Lee, Sul A, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Lafargue, Marie-Camille, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Williams, Winfred W., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Gilligan, Hannah M., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Safa, Kassem, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Cohen Bucay, Abraham, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Nissaisorakarn, Pitchaphon, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Al Jurdi, Ayman, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Jüppner, Harald, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Low, Susan, eGenesis Inc, Cambridge, Massachusetts, United States
  • Curtis, Michael, eGenesis Inc, Cambridge, Massachusetts, United States
  • Riella, Leonardo V., Massachusetts General Hospital, Boston, Massachusetts, United States

Group or Team Name

  • Mass General Kidney Transplant Team and eGenesis Team
Background

Although kidney transplantation is the preferred treatment for ESKD, organ shortages severely limit timely access to transplants. Pig-to-human xenotransplantation has been proposed to address this issue, but concerns remain about meeting the physiologic needs of a living human and the potential incompatibility between humans and pigs. Here, we present several physiologic aspects of a gene-edited porcine xenograft in the first living human recipient during 51 days of follow-up.

Methods

A 62-year-old male with ESKD due to diabetes on hemodialysis, who was facing ongoing vascular access challenges, had no living donor options and an expected wait time for a deceased donor kidney exceeding 5 years, was selected for xenotransplantation with a 69-gene-edited porcine kidney donor.

Results

Kidney excretory function was assessed by BSA-adjusted 24-hour urine creatinine clearance (CrCl), Cr-based estimated GFR (eGFR), and cystatin C-based eGFR. The xenograft eGFR was 45-55 ml/min/1.73m2 with a strong correlation among Cr- and Cystatin C-based eGFR (r=0.9). The 24-hour urine CrCl was generally higher than Cr-based eGFR by 7-14 ml/min/1.73m2. Despite concerns about inefficient human angiotensinogen activation by pig renin, the recipient maintained hemodynamic stability post-transplantation. To gauge human anti-diuretic hormone compatibility on porcine kidneys, the osmoregulatory function of the xenograft was evaluated. The electrolyte-free water excretion was 0.5-1.5 L/day with fluctuating serum sodium levels within the normal range. The urine osmolality ranged between 220-670 mOsm/kg H2O. No albuminuria or hematuria was observed post-transplantation. The recipient developed hypocalcemia (8.0±0.5 mg/dL) and hyperphosphatemia (6.7±0.7 mg/dL) post-transplantation, possibly in part related to iatrogenic hypoparathyroidism from prior parathyroidectomy (PTH undetectable). Fractional excretion of phosphorus stayed low (<10%) despite elevated intact fibroblast growth factor 23 (FGF-23).

Conclusion

This case report suggests that the xenograft maintained excretory function, hemodynamic stability, and urinary concentrating capacity during follow-up. While lack of PTH may have contributed to hypocalcemia and reduced phosphate excretion, further investigation into the potential incompatibility of human FGF23 on porcine kidneys is needed.